STXC
ActiveFrom the official registers: KBO 11 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
STXC has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €199,660 and a net result of €179,255. Equity has been growing by about 14% per year since 2018. Its solvency ranks better than 91% of 615 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Official details
KBO- Status
- Active since 02-06-2015 Normal situation
- Activity
- Research and development on biotechnology NACE 72101
- Establishment unit
- 2.242.766.890 9300 Aalst, since 01-07-2015
- Financial year end
- 31 December
- Peppol
- Reachable since 07-11-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
- Gross margin
- €242,147
- ▲ 63.2%
- Turnover
- ≈ €610,000
- estimated
- Profit
- €179,255
- ▲ 61.9%
- Equity
- €199,660
- ▲ 52.3%
- Total assets
- €210,455
- ▲ 51.1%
Score breakdownlowers riskLiquidity: current ratio 17.78, cash €159,524Equity €199,660 (94.9% of total assets)Size: total assets €210,455Sector: Scientific research and development (NACE 72)Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 83% of them on solvency, 96% on liquidity, 90% on profitability and 87% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 34 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: Higher net result than 90% of companies in research and developmentsector median €27,193 · 615 companies €179,255 View
- Positive: Result rose in 2025from €110,716 to €179,255 ▲ 61.9% View
- Positive: 8 profitable years in a rowprofit 2025: €179,255 8 years View
- Positive: Filed on time since financial year 2020accounts within the deadline every year 6 years View
Comparable companies
These companies have the same main activity as STXC: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €216,000 and €444,000, founded between 2010 and 2018.
| Company | Total assets | Gross margin |
|---|---|---|
| STXC Aalst | €210,455 | €242,147 |
| THALEN BIOTECH CONSULTANCY Frasnes-lez-Anvaing | €215,550 | €221,552 |
| SUSTAINEER Gent | €299,595 | €116,857 |
| BIOSILARIS Huy | €261,445 | €93,489 |
| CRz Services Spa | €251,152 | €82,779 |
| DOKTER BAMELIS MIA, DERMATOLOOG Aalst | €350,356 | €100,598 |
| IndusFilter Gent | €443,685 | €226,240 |
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 16-06-2026
- Annual accounts 2024filed on 24-06-2025
- Annual accounts 2023filed on 07-06-2024
- Annual accounts 2022filed on 09-06-2023
Acts in the Belgian Official Gazette
- General meeting · Approvalact of 24-06-2025
Articles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about STXC
- What is the company number of STXC?
- The company number of STXC is 0631.695.672. The VAT number is the same number with BE in front: BE 0631.695.672.
- Where is STXC based?
- The registered office is at Caudronstraat 10, 9300 Aalst.Company details
- What does STXC do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of STXC?
- The legal form of STXC is Private limited company (pre-2019) (BVBA).
- When was STXC founded?
- STXC was founded on 02-06-2015.
- Is STXC still active?
- Yes, STXC is an active enterprise in the KBO register.
- What is the turnover of STXC?
- The turnover in financial year 2025 is ≈ €610,000. This figure is estimated from the gross margin of €242,147 and 2,213 comparable companies of the same size. It probably lies between €410,000 and €940,000. It is a rough estimate.Financials
- Is STXC profitable?
- In financial year 2025, STXC made a profit of €179,255.
- Where can I find the annual accounts of STXC?
- STXC filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
- When are the next annual accounts of STXC due?
- STXC must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.